Freya has developed GPX-506a-c – fortified antibiotics, cyclosporine and ketotifen eluting contact lenses to provide sustained release resulting in therapeutic concentrations for extended durations, eliminating the peaks and troughs in concentrations from drops, which may cause sub-therapeutic concentration between drop instillations, which can lead to infection proliferation and/or development of resistance